Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

By David M. Mannino, D. Thorn, A. Swensen, F. Holguin. European Respiratory Journal, 2008

1,221 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a22e14c25cc189139698d0b7271a7ac43a578d05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. P. Barnes
2. P. Calverley
3. W. Macnee
4. D. Parums

In Pulmonary and Respiratory Medicine

1. D. Parums
2. P. Barnes
3. P. Calverley
4. K. Rabe
5. A. Anzueto
6. Jorgen Vestbo
7. R. Stockley
8. R. Rodríguez-Roisín

Citations in the corpus

• Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary (2023, neutral): “hypertension 175,176 venous thromboembolism 176 and mortality. following the introduction of long-term oxygen therapy (LTOT), 177 178”
• Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, neutral): “Сопутствую щие заболевания могут иметь место у пациентов с лег ким, средней тяжести и тяжелым ограничением воздуш ного потока [131], оказывают независимое влияние на смертность и частоту госпитализаций [142] и требуют специального лечения.”
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “Studies have shown that the metabolic syndrome and manifest diabetes are more frequent in COPD, and the latter is likely to impact on prognosis (169).”
• Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. (2012, background): “However, these studies were not planned to systematically evaluate the prevalence and role of comorbidity in COPD, several were performed in single centers with small number of patients (12, 14), used retrospective administrative databases (6, 17, 18), or enrolled patients admitted in the acute care”
• Chronic obstructive pulmonary disease phenotypes: the future of COPD. (2010, background): “In particular, diabetes, hypertension, cardiovascular disease, and cancer increase the risk of death in COPD (51).”
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “Metabolic syndrome and diabetes are more frequent in COPD and the latter is likely to affect prognosis.(302) The prevalence of metabolic syndrome has been estimated to be more than 30%.”
• Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. (2013, methodology): “TNF-R1, pg/ml 2,013 (1,508, 2,689) 2,229 (1,513, 3,285) 1,896 (1,434, 2,505) 2,377 (1,850, 3,055)* 2,133 (1,685, 2,699) TNF-R2, pg/ml 3,417 (2,454, 4,758) 3,698 (2,399, 5,701) 3,302 (2,478, 4,401) 4,080 (3,115, 5,344)* 3,419 (2,675, 4,371) Leukocytes, 310(9)/L 7.”